Susceptibilities of clinical isolates to tazobactam/piperacillin and other antimicrobial agents as of 2012

Keizo Yamaguchi, Yoshikazu Ishii, Kazuhiro Tateda, Chikara Shimizu, Akira Suwabe, Mitsuo Kaku, Akira Hishinuma, Shigefumi Maesaki, Mitsuru Murata, Tetsuya Matsumoto, Hinako Murakami, Yoshihito Otsuka, Masato Maekawa, Tetsuya Yagi, Yuka Yamagishi, Shinichi Fujita, Yukio Hida, Kaname Nakatani, Satoshi Ichiyama, Ikuko FujimotoHisashi Kohno, Kazuyuki Okuda, Nobuchika Kusano, Yukinori Kurokawa, Yaeko Watanabe, Kiyoshi Negayama, Hitoshi Miyamoto, Makiko Kiyosuke, Kouichi Mashiba, Katsunori Yanagihara, Yosuke Aoki, Kazufumi Hiramatsu

Research output: Contribution to journalArticle

Abstract

Surveillance of β-lactamase production and susceptibilities to antimicrobial agents including tazobactam/piperacillin (TAZ/PIPC) in 3,952 bacterial strains isolated in 2012 were conducted in Japan. β-lactamase production was investigated in over 80% of the strains of Moraxella catarrhalis, Escherichia coli, Citrobacter spp., Klebsiella pneumoniae, Enterobacter cloacae, Serratia marcescens, indole-positive Proteus spp., Providencia spp., Pseudomonas aeruginosa, Acinetobacter spp. and Bacteroides fragilis group. Extended spectrum β-lactamase-producing strains in E. coli, K. pneumoniae and P. mirabilis were 19.0%, 7.2% and 8.2%, respectively. Metallo-β-lactamase producers in P. aeruginosa and Acinetobacter spp. were 1.0% and 0.4%, respectively, and no strain of E. cloacae and S. marcescens was detected. Susceptibility of 3,952 strains to TAZ/PIPC based on the criteria of the Clinical and Laboratory Standards Institute or European Committee on Antimicrobial Susceptibility testing were distributed from 79.2% in E.cloacae to 100% in methicillin-susceptible S. aureus, coagulase-negative staphylococci, M. catarrhalis, P. mirabilis, indole-positive Proteus spp. and H. influenzae including β-lactamase-negative ampicillin-resistant strains. When compared with those in previous investigations conducted in 2010, the susceptibility to TAZ/PIPC had not changed. From these results, TAZ/PIPC is considered as a useful initial therapeutic antimicrobial agent for infectious diseases.

Original languageEnglish
Pages (from-to)668-680
Number of pages13
JournalJapanese Journal of Chemotherapy
Volume64
Issue number4
Publication statusPublished - 2016 Jul

Keywords

  • CLSI
  • EUCAST
  • Susceptibility
  • Tazobactam/piperacillin
  • β-lactamase

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Fingerprint Dive into the research topics of 'Susceptibilities of clinical isolates to tazobactam/piperacillin and other antimicrobial agents as of 2012'. Together they form a unique fingerprint.

  • Cite this

    Yamaguchi, K., Ishii, Y., Tateda, K., Shimizu, C., Suwabe, A., Kaku, M., Hishinuma, A., Maesaki, S., Murata, M., Matsumoto, T., Murakami, H., Otsuka, Y., Maekawa, M., Yagi, T., Yamagishi, Y., Fujita, S., Hida, Y., Nakatani, K., Ichiyama, S., ... Hiramatsu, K. (2016). Susceptibilities of clinical isolates to tazobactam/piperacillin and other antimicrobial agents as of 2012. Japanese Journal of Chemotherapy, 64(4), 668-680.